IQVIA and SCRI partner to enhance oncology trials
IQVIA has partnered with SCRI Development Innovations, the contract research organisation branch of the Sarah Cannon Research Institute (SCRI), aimed…
Oncology
-
-
Sellas doses first paediatric subject with AML in Phase II trial of SLS009
Sellas Life Sciences has dosed the first paediatric subject with acute myeloid leukaemia (AML) in its multi-centre Phase II trial…
-
MSD’s Phase III trial of Keytruda meets endpoint for treating ovarian cancer
MSD has reported that the randomised Phase III KEYNOTE-B96 trial of Keytruda (pembrolizumab) plus chemotherapy (paclitaxel), with or without bevacizumab,…
-
First subject dosed in Revolution Medicines’ Phase III NSCLC treatment trial
Revolution Medicines has dosed the first subject in the Phase III RASolve 301 trial with the RAS (ON) multi-selective inhibitor,…
-
ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data
ADC Therapeutics has culled its clinical asset ADCT-602 while announcing more data on its flagship drug Zynlonta (loncastuximab tesirine-lpyl). Following…
-
Roche reports final overall survival outcomes from breast cancer treatment trial
Swiss pharmaceutical company Roche has reported final overall survival outcomes from a long-term Phase III trial of Perjeta (pertuzumab) with…
-
GSK and iTeos drop anti-TIGIT drug following trial failure
GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a…
-
Leucid Bio starts dosing in trial of LEU011 for refractory solid tumours
UK-based Leucid Bio has dosed the first subject in the multi-centre Phase I AERIAL trial of autologous lateral chimeric antigen…
-
GLP-1RAs show anti-cancer benefits beyond weight loss
A study has found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer anti-cancer benefits that extend beyond their role in promoting…
-
EMA approves Moleculin’s application for Phase IIb/III AML trial
The European Medicines Agency (EMA) has approved Moleculin Biotech’s clinical trial application (CTA) for a pivotal, multi-centre Phase IIb/III trial…
